Gene products differentially expressed in cancerous breast cells and their methods of use
OwnerRhonda Hanseninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in breast cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of breast cancer cells. These methods are useful for treating breast cancer.
Claims30
A method for inhibiting a cancerous phenotype of a cell, said method comprising:
- contacting a cancerous mammalian cell with an agent for inhibition of DKFZp5661133 activity.
The method of claims 1-6, wherein said inhibition is associated with a reduction in a level of DKFZp566I133 protein.
The method of claims 1-7, wherein said inhibition is associated with a reduction in a level of DKFZp566I133 RNA.
The method of claims 1-8, wherein said inhibition is associated with a reduction in a level of activity of DKFZp566I133 protein.
A method for detecting a cancerous cell, said method comprising:
- detecting a level of DKFZp566I133 or fragment thereof in a test sample obtained from a cell of a subject,
- comparing the level of DKFZp566I133 to a control level of DKFZp5661133,
- wherein the presence of a cancerous cell is indicated by detection of said level and comparison to a control level of DKFZp566I133.
A method of treating a subject with cancer, said method comprising:
- administering to a subject a pharmaceutically effective amount of an agent, wherein said agent modulates the activity of DKFZp566I133.
A method for assessing the tumor burden of a subject, said method comprising:
- detecting a level of DKFZp566I133 in a test sample from a subject,
- wherein the level of DKFZp566I133 in the test sample is indicative of the tumor burden in the subject.
A method for identifying an agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:
- contacting a candidate agent with a DKFZp566I133;
- and
- detecting modulation of a biological activity of DKFZp566I133 relative to a level of biological activity of DKFZp566I133 in the absence of the candidate agent.
An isolated polynucleotide comprising at least 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:1-499.
Dependencies are inferred from the claim text.